Developing Vonafexor and analogs as strong antifibrotic and anti-inflammatory therapeutics currently in clinical stage for rare and common renal diseases like Alport syndrome and CKD
Time: 11:30 am
day: Day One Track 2 AM
Details:
- Phase 2 “ALPESTRIA-1” trial is ongoing as a PoC with Vonafexor in Alport syndrome (topline data – Q4-2025).
- PoC Phase 2 trial is ready to start with Vonafexor analog for grade 3 CKD patients having MASH to confirm the LIVIFY trial results.
- Validating the unique mechanism of action of Vonafexor and its analogs compared to other FXR agonists.
